tradingkey.logo

ANI Pharmaceuticals Inc

ANIP
80.340USD
-1.500-1.83%
收盘 02/09, 16:00美东报价延迟15分钟
269.63M总市值
47.05市盈率 TTM

ANI Pharmaceuticals Inc

80.340
-1.500-1.83%

关于 ANI Pharmaceuticals Inc 公司

ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company engaged in developing, manufacturing, and commercializing therapeutics. Its Rare Disease and Brands segment consists of two reporting units. The Rare Disease unit consists of operations related to the development, manufacturing, and marketing of branded pharmaceutical products, with a focus on products used in the treatment of patients with rare disease conditions and consists of operations related to Cortrophin Gel, ILUVIEN and YUTIQ. In addition, the Brands reporting unit includes a portfolio of over 16 brand products that are principally sold in genericized markets. Its Generics and Other segment consist of operations related to the development, manufacturing, and marketing of generic pharmaceutical products, including those sold through traditional wholesale and retail sales channels, sales of contract manufactured products, royalties on contract manufactured products, product development services, and others.

ANI Pharmaceuticals Inc简介

公司代码ANIP
公司名称ANI Pharmaceuticals Inc
上市日期May 04, 2000
CEOLalwani (Nikhil Suresh)
员工数量897
证券类型Ordinary Share
年结日May 04
公司地址210 Main Street West
城市BAUDETTE
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编56623
电话12186343500
网址https://www.anipharmaceuticals.com/
公司代码ANIP
上市日期May 04, 2000
CEOLalwani (Nikhil Suresh)

ANI Pharmaceuticals Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-56960.00%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+23936.00%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+10262.00%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-5873.00%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
58.56K
-1622.00%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-11643.00%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
40.04K
-4975.00%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
36.52K
-19341.00%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
25.16K
-1800.00%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
6.86K
-9465.00%
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
411.22K
-56960.00%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+23936.00%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+10262.00%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
84.02K
-5873.00%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
58.56K
-1622.00%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
58.41K
-11643.00%

收入明细

单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Sales of Cortrophin Gel
101.85M
44.71%
Generic pharmaceutical products
94.38M
41.43%
Sales of ILUVIEN and YUTIQ
16.60M
7.29%
Brand
10.68M
4.69%
Royalty and other
4.31M
1.89%
由于公司未披露,未能获取相关数据
业务
地区
业务USD
名称
营收
占比
Sales of Cortrophin Gel
101.85M
44.71%
Generic pharmaceutical products
94.38M
41.43%
Sales of ILUVIEN and YUTIQ
16.60M
7.29%
Brand
10.68M
4.69%
Royalty and other
4.31M
1.89%

股东统计

更新时间: 2月1日 周日
更新时间: 2月1日 周日
持股股东
股东类型
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.79%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
其他
73.27%
持股股东
持股股东
占比
BlackRock Institutional Trust Company, N.A.
10.43%
The Vanguard Group, Inc.
5.79%
Meridian Venture Partners
4.52%
State Street Investment Management (US)
3.17%
Esjay L.L.C,
2.82%
其他
73.27%
股东类型
持股股东
占比
Investment Advisor
39.61%
Investment Advisor/Hedge Fund
23.14%
Hedge Fund
19.38%
Individual Investor
7.44%
Research Firm
6.42%
Private Equity
4.52%
Corporation
2.84%
Pension Fund
1.66%
Bank and Trust
1.31%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
526
21.60M
96.19%
-1.02M
2025Q3
525
21.96M
103.27%
+407.79K
2025Q2
506
21.46M
110.44%
-446.10K
2025Q1
489
21.61M
106.49%
-1.37M
2024Q4
469
21.12M
108.93%
+156.97K
2024Q3
453
20.75M
88.54%
+3.60M
2024Q2
425
17.36M
85.19%
+1.07M
2024Q1
403
16.22M
82.13%
-1.01M
2023Q4
390
16.10M
82.95%
+39.70K
2023Q3
378
15.97M
79.12%
+734.26K
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
BlackRock Institutional Trust Company, N.A.
2.34M
10.43%
-29.49K
-1.24%
Sep 30, 2025
The Vanguard Group, Inc.
1.27M
5.67%
+116.00
+0.01%
Sep 30, 2025
Meridian Venture Partners
1.01M
4.52%
-150.00K
-12.88%
Aug 21, 2025
State Street Investment Management (US)
711.71K
3.17%
-4.41K
-0.62%
Sep 30, 2025
Esjay L.L.C,
632.62K
2.82%
-200.00K
-24.02%
Mar 14, 2025
Global Alpha Capital Management Ltd.
630.59K
2.81%
-231.50K
-26.85%
Sep 30, 2025
Citadel Advisors LLC
580.09K
2.58%
+10.46K
+1.84%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
505.43K
2.25%
-48.47K
-8.75%
Sep 30, 2025
Geode Capital Management, L.L.C.
458.01K
2.04%
+30.47K
+7.13%
Sep 30, 2025
Deep Track Capital LP
450.00K
2%
-250.00K
-35.71%
Sep 30, 2025
查看更多

持股ETF

更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
Invesco Pharmaceuticals ETF
2.63%
State Street SPDR S&P Pharmaceuticals ETF
2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.63%
Innovator IBD Breakout Opportunities ETF
1.38%
Innovator IBD 50 Fund ETF
1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
0.98%
Invesco S&P SmallCap Health Care ETF
0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.92%
First Trust Small Cap Growth AlphaDEX Fund
0.67%
查看更多
Invesco Pharmaceuticals ETF
占比2.63%
State Street SPDR S&P Pharmaceuticals ETF
占比2.42%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比1.95%
Pacer US Small Cap Cash Cows Growth Leaders ETF
占比1.63%
Innovator IBD Breakout Opportunities ETF
占比1.38%
Innovator IBD 50 Fund ETF
占比1.02%
Invesco Dorsey Wright Healthcare Momentum ETF
占比0.98%
Invesco S&P SmallCap Health Care ETF
占比0.96%
Janus Henderson Small/Mid Cap Growth Alpha ETF
占比0.92%
First Trust Small Cap Growth AlphaDEX Fund
占比0.67%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
KeyAI